DURHAM, N.C., November 16, 2016 — From discovery to approval to market entry, patient advocacy groups are quickly expanding their role in drug development as they target vast unmet needs in cancer and rare disease treatment. One of Premier Research’s rare disease strategists will discuss this trend, and its implications for the industry, at this year’s World Orphan Drug Congress in Brussels.
Juliet Moritz, Executive Director of Strategic Development for Rare Disease, will present The Evolving Relationship Between Researchers and Patient Advocates on Wednesday, November 16, at 5:25pm CEST.
Once relegated largely to fundraising and lobbying, many advocates are assuming far more significant roles — even directly funding clinical trials and assisting with study design. It’s prompting highly productive dialogue that is advancing the cause of scientific discourse, and industry is taking innovative steps to make the most of these relationships.
Moritz and other Premier Research rare disease experts will be available for meetings throughout the conference.
About Premier Research
Premier Research is a leading clinical development service provider that helps highly innovative biotech and specialty pharma companies transform breakthrough ideas into reality. The company has a wealth of experience in the execution of global, regional and local clinical development programs with a special focus on addressing unmet needs in areas such as analgesia, dermatology, medical device, neuroscience, oncology, pediatric, and rare disease. Premier Research operates in 84 countries and employs 1,000 professionals, including a strong international network of clinical monitors and project managers, regulatory, data management, statistical, scientific, and medical experts. They are focused on smart study design for advanced medicines that allow life-changing treatments.